Overview

Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The study should evaluate distribution of [123I] I-(HE)3-G3 in patients with primary HER2-positive and HER2-negative breast cancer
Phase:
Phase 1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences